Physician profile
Narae Ko
NPI 1649532276
$6,959.75
in general payments reported to CMS, 2019-2025
19 companies · $1,215 in 2025
The $1,215 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $297 · 2021: $564 · 2022: $1,782 · 2023: $1,432 · 2024: $1,202 · 2025: $1,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,487 · Travel and Lodging: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,487.32 |
| Travel and Lodging | $360.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,641.73 | 2019-2025 | Wavelight Refractive Suite, Clareon, Wavelight Ex500 Excimer Laser |
| Glaukos Corporation | $1,016.32 | 2019-2021 | |
| Oyster Point Pharma, INC. | $706.59 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $678.23 | 2022-2025 | Cequa |
| Bausch & Lomb Americas INC. | $407.30 | 2022-2025 | Xiidra, Vyzulta, Miebo |
| Abbvie INC. | $388.40 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $312.71 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $243.35 | 2020-2023 | |
| Dompe US, INC. | $152.69 | 2022-2025 | Oxervate |
| Ocular Therapeutix, INC. | $111.66 | 2022-2025 | Dextenza |
| Amgen INC. | $90.74 | 2024-2025 | Tepezza |
| Rxsight INC | $41.83 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Johnson & Johnson Surgical Vision, INC. | $37.02 | 2024 | Lipiflow System Activator II (Disposable |
| Rayner Intraocular Lenses Limited | $35.20 | 2022 | |
| Eyevance Pharmaceuticals LLC | $30.61 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $20.77 | 2023 | Vevye |
| Regeneron Healthcare Solutions, INC. | $16.56 | 2019 | |
| Lkc Technologies, INC. | $14.65 | 2023 | |
| Allergan, INC. | $13.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narae Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.